Q32 Bio Inc. (QTTB): restructuring charge — Q32 Bio restructures to focus on bempikibart; discontinues ADX-097 renal trial, cuts workforce

Q32 Bio Inc.

Restructuring prioritizes bempikibart for alopecia areata; discontinues Phase 2 renal basket trial for ADX-097.
Expects $1.1M severance charges; cash runway extended to second half of 2026.
Open-label extension for SIGNAL-AA Part A initiates in 1H'25; Part B dosing starts 1H'25 with topline data expected 1H'26.
Evaluating strategic options for tissue-targeted complement inhibitor platform, including ADX-097 and early-stage assets.

Key facts

Extracted from this filing and checked against the source text.

Restructurings & Charges SEC 8-K Item 2.05/2.06 confidence 0.9

Q32 Bio Inc. announced a restructuring with charges of approximately $1.1 million affecting general operations; discontinuing Phase 2 renal basket trial of ADX-097; evaluating strategic options for tissue-targeted complement inhibitor platform (reduction in force).

Type: restructuring
Charge: approximately $1.1 million
Affected area: general operations; discontinuing Phase 2 renal basket trial of ADX-097; evaluating strategic options for tissue-targeted complement inhibitor platform
Headcount: reduction in force

Exact text from the filing

the Company expects to incur severance and severance-related charges of approximately $1.1 million

View on SEC.gov

Browse all restructurings & charges →

Q32 Bio Inc. filing history →

Source: SEC EDGAR

accession 0000950170-25-017075

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.